{"id":390540,"date":"2018-11-29T00:00:00","date_gmt":"2018-11-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcv0002-2018-biopharma-pulmonary-hypertension-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-04-15T09:55:33","modified_gmt":"2026-04-15T09:55:33","slug":"dlsfcv0002-2018-biopharma-pulmonary-hypertension-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcv0002-2018-biopharma-pulmonary-hypertension-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Pulmonary Hypertension | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p>Pulmonary hypertension (<abbr data-original-title=\"pulmonary hypertension\" title=\"\">PH<\/abbr>) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable, driven by the premium price that may be charged for\u00a0<abbr data-original-title=\"pulmonary hypertension\" title=\"\">PH<\/abbr>\u00a0agents. Commercial interest in\u00a0<abbr data-original-title=\"pulmonary hypertension\" title=\"\">PH<\/abbr>\u00a0is high as a result of recent and significant advances in the understanding of its etiology and pathophysiology and the emergence of new therapies to treat the disease.<\/p>\n<p>Geographies:<\/p>\n<p>United States, EU5, Japan<\/p>\n<p>Key Drugs Covered:<\/p>\n<p>Uptravi, Orenitram, Adempas, Opsumit, Adcirca, Tracleer, Revatio, Letairis\/Volibris, Remodulin, Flolan, Veletri, Tyvaso, Ventavis, Beraprost, ralinepag, esuberaprost, bardoxolone\u00a0methyl, inhaled\u00a0dry powder treprostinil, INOpulse<\/p>\n<p>Key Companies Mentioned:<\/p>\n<p>Actelion \u00b7 United Therapeutics \u00b7 Bayer Healthcare \u00b7 GlaxoSmithKline \u00b7 Gilead Sciences \u00b7 Pfizer\u00a0\u00b7 Arena Pharmaceuticals \u00b7 Mannkind\u00a0Corporation \u00b7 Bellerophon\u00a0Therapeutics\u00a0\u00b7 Liquidia\u00a0Technologies \u00b7 Reata Pharmaceuticals<\/p>\n","protected":false},"template":"","class_list":["post-390540","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hypertension","biopharma-therapy-areas-pulmonary-hypertension","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390540\/revisions"}],"predecessor-version":[{"id":393664,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390540\/revisions\/393664"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}